Hospitals being bribed to use remdisvir
CMS.gov Chart Shows How Hospitals Are Being Bribed To Use
Deadly Remdesivir And Get $39,000 To Put People On Ventilators!
Print This Out And Take To The Hospital!
10-4-21
New COVID-19 Treatments Add-On Payment (NCTAP)
CMS issued an Interim Final Rule with Comment Period that established the New COVID-19 Treatments Add-on Payment (NCTAP) under the Medicare Inpatient Prospective Payment System (IPPS). The NCTAP, designed to mitigate potential financial disincentives for hospitals to provide new COVID-19 treatments, is effective from November 2, 2020, until the end of the COVID-19 public health emergency (PHE).
Through the NCTAP, the Medicare Program will provide an enhanced payment for eligible inpatient cases that use certain new products with current FDA approval or emergency use authorization (EUA) to treat COVID-19, including the following:
On August 23, 2020, the FDA issued (reissued on November 30, 2020, and revised on March 9, 2021) an EUA for the use of COVID-19 convalescent plasma for treating COVID-19 in hospitalized patients
On October 22, 2020, the FDA approved remdesivir (Veklury) for the treatment of COVID-19 for adults and certain pediatric patients requiring hospitalization
On November 19, 2020, the FDA issued an EUA for the use of baricitinib (Olumiant), in combination with remdesivir (Veklury), for the treatment of suspected or laboratory confirmed COVID-19 in certain hospitalized patients
For eligible cases, the NCTAP is equal to the lesser of these:
65% of the operating outlier threshold for the claim
65% of the amount by which the costs of the case exceed the standard Diagnosis-Related Group (DRG) payment (including the adjustment to the relative weight under Section 3710 of the Coronavirus Aid, Relief, and Economic Security Act (CARES Act)
Coding for NCTAP
NCTAP claims are those that are eligible for the 20% add-on payment under Section 3710 of the CARES Act. Eligible claims have both of the following:
ICD-10-CM diagnosis code U07.1 (COVID-19)
ICD-10-PCS codes for remdesivir (Veklury), COVID-19 convalescent plasma, or baricitinib (Olumiant) in combination with remdesivir, as described below
Codes for Remdesivir or COVID-19 Convalescent Plasma for Hospital Discharges on or after November 2, 2020
ICD-10-PCS Code Description
XW033E5 Introduction of remdesivir anti-infective into peripheral vein, percutaneous approach, new technology group 5
XW043E5 Introduction of remdesivir anti-infective into central vein, percutaneous approach, new technology group 5
XW13325 Transfusion of convalescent plasma (nonautologous) into peripheral vein, percutaneous approach, new technology group 5
XW14325 Transfusion of convalescent plasma (nonautologous) into central vein, percutaneous approach, new technology group 5
Codes for Baricitinib for Hospital Discharges between November 19, 2020 and December 31, 2020*
ICD-10-PCS Code Description
XW0DXF5 Introduction of other new technology therapeutic substance into mouth and pharynx, external approach, new technology group 5
3E0G7GC Introduction of other therapeutic substance into upper G.I. via natural or artificial opening
3E0H7GC Introduction of other therapeutic substance into lower G.I. via natural or artificial opening
